AI Article Synopsis
- The study aimed to assess how (18)F-FDG PET scans influence treatment decisions in patients with suspected colorectal cancer recurrence in a real clinical setting.
- PET scans led to management changes in 59% of the patients, with oncologists adjusting their plans based on unexpected findings from the scans.
- The findings highlight the effectiveness of PET in correctly identifying the presence and extent of disease, although there were some false positives and underestimations of metastases.
Article Abstract
Unlabelled: This prospective study aimed to confirm, in a clinical setting, the benefits suggested by earlier retrospective studies of (18)F-FDG PET scanning for the evaluation of patients with suspected recurrence of colorectal cancer.
Methods: The referring oncologist was asked to prospectively assign a treatment plan for 102 consecutive patients being evaluated by (18)F-FDG PET for suspected or confirmed recurrence of colorectal cancer and without evidence of unresectable disease on conventional staging investigations, including CT. This treatment plan was then compared with that based on incremental information supplied by PET. Management changes were validated by follow-up.
Results: For 6 patients, the oncologist would not commit to a management plan without access to PET information, and for all these patients, PET correctly guided management. Of the remaining 96 patients, the management plan for 54 (56%) was altered as a direct result of unexpected PET findings. Thus, PET directly influenced management in 60 (59%) of 102 patients. The discrepant PET results could be validated in 57 patients and were correct for both the presence and the extent of malignant disease in 52 (91%) of these patients but were false-positive in 1 patient because of a pelvic abscess and underestimated the extent of metastatic disease in 4 (7%). Relapse was confirmed in 49 (98%) of 50 evaluable patients with positive PET findings. Significantly, planned surgery was abandoned in 26 (60%) of 43 patients because of incremental PET findings. Of the 42 patients for whom management was not changed by PET findings, false-negative PET findings were documented for 5 (4 with metastases < 1 cm), and the PET findings for 1 were presumed to be false-positive because of sarcoidosis.
Conclusion: This prospective study confirms the high impact, suggested by previous retrospective analyses, of (18)F-FDG PET on management of patients with suspected recurrent colorectal cancer. The major benefit of PET is avoidance of inappropriate local therapies by documentation of widespread disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tornado sheltering: Challenges and solutions including public storm shelters.
J Emerg Manag
January 2024
Department of Geosciences, Mississippi State University, Mississippi State, Mississippi.
Tornadoes are a considerable threat across the United States, occurring in many regions of the country on a frequent basis throughout the year. Finding a safe place to go during a tornado can be a challenge for many individuals, and, in some situations, there is no safe place available. Increasing the number of tornado shelters and establishing them in regions where they are not currently present can greatly improve the safety of local residents and visitors, especially for those who are unable to afford retrofitting a shelter into their own home or business.
View Article and Find Full Text PDFUpdated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
Alzheimers Dement
January 2025
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Introduction: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET.
Methods: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered.
Maximum Tumor Diameter is Associated with Relapse Risk in Limited-Stage Hodgkin Lymphoma: An International Study.
Blood Adv
January 2025
Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, and Department of Medical Oncology, The Christie Hospital, Manchester, United Kingdom.
Tumour bulk is an established prognostic factor in Hodgkin lymphoma (HL) but most patients with limited-stage (LS) HL do not have 'bulk' by standard binary definitions. In the RAPID trial, maximum tumor diameter (MTD) was associated with risk of relapse for LS-HL patients achieving PET-negativity after ABVD chemotherapy. We aimed to externally validate these findings in the H10 trial.
View Article and Find Full Text PDFFDG PET/CT in a Case of Metastasizing Pleomorphic Adenoma in the Ilium.
Clin Nucl Med
November 2024
Department of Orthopedics, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Although pleomorphic adenomas of the salivary glands are benign tumors, they can metastasize to distant organs without evidence of malignant transformation. We describe FDG PET/CT finding in a case of metastasizing pleomorphic adenoma in the right ilium occurring 22 years after initial surgical resection of a lip pleomorphic adenoma. On FDG PET/CT, the iliac metastasis appeared as an expansile osteolytic lesion with heterogeneous activity.
View Article and Find Full Text PDFUncovering Hidden Metastases at Unusual Site: Emphasizing the Role of 177Lu-PSMA Posttherapy Scan in Detecting Rare Foot Metastasis in mCRPC.
Clin Nucl Med
November 2024
From the Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Prostate cancer frequently metastasizes to bones; however, the detection of metastases can be challenging in rare locations. We present the case of a 76-year-old man with metastatic castration-resistant prostate cancer with lymph nodal and skeletal metastases who underwent 177Lu-prostate-specific membrane antigen (PSMA) therapy. Initial 18F-PSMA PET/CT scan acquired until the midthigh failed to identify metastases in the foot, but posttherapy 177Lu-PSMA scan revealed the presence of metastases in the navicular and cuboid bones of the right foot, which is a very rare finding.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!